Phaseline

Companies › Cell Energy Life Sciences Group

Cell Energy Life Sciences Group: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Infectious disease, Oncology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
mesenchymal stem cell (umbilical cord derived MSCs)
Cell therapy with mesenchymal stem cells
–Phase 1AIDS; COVID-19 InfectionJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05939167mesenchymal stem cell (umbilical cord derived MSCs)Phase 1AIDSInfectious diseaseJul 2027
NCT04565665mesenchymal stem cell (umbilical cord derived MSCs)Phase 1COVID-19 InfectionOncologyOct 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.